Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03754803Completed

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

Role: collaborator

NCT03518060Completed

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

Role: collaborator

NCT03158987Completed

Regional Differences in Human Immunodeficiency Virus (HIV) Testing

Role: collaborator

NCT00908544Not ApplicableCompleted

New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients

Role: lead

NCT02203461Phase 1Completed

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Role: collaborator

All 5 trials loaded